Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.90 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.90 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.90 |
| ▸ | RECQL | P46063 | 1/20 | 0.90 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.63 |
| ▸ | HRH1 | P35367 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.62 |
| ▸ | TP53 | P04637 | 3/20 | 0.62 |
| ▸ | TSHR | P16473 | 3/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.62 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | THPO | P40225 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levocarnitine Propionate SCHEMBL464940 | 0.95 | MEN1 (1.00) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| Propionyl-Carnitine SCHEMBL156850 | 0.95 | MEN1 (1.00) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| Propionyl-Carnitine SCHEMBL994714 | 0.95 | MEN1 (1.00) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| Propionyl-Carnitine SCHEMBL1358526 | 0.93 | MEN1 (0.97) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| Levocarnitine Propionate SCHEMBL3005249 | 0.93 | MEN1 (0.97) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| Levocarnitine Propionate SCHEMBL1358528 | 0.93 | MEN1 (0.97) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| Propionyl-Carnitine SCHEMBL3639171 | 0.92 | MEN1 (0.82) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| Levocarnitine Propionate SCHEMBL3039334 | 0.92 | MEN1 (0.82) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| Propionyl-Carnitine SCHEMBL3637406 | 0.91 | MEN1 (0.80) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| Levocarnitine Propionate SCHEMBL3637409 | 0.91 | MEN1 (0.80) | MEN1KMT2ACYP2C19RECQLCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11364214-B2 | Compositions and methods for treating eczema | DERMALA, INC. (US) | 2022-06-21 | — | — | US | disclosed |
| US-20190290605-A1 | COMPOSITIONS AND METHODS FOR TREATING ECZEMA | DERMALA INC (US) | 2019-09-26 | — | — | US | disclosed |
| EP-3458158-A1 | COMPOSITIONS AND METHODS FOR TREATING ECZEMA | Dermala Inc. (US) | 2019-03-27 | — | — | EP | disclosed |
| WO-2017201297-A1 | COMPOSITIONS AND METHODS FOR TREATING ECZEMA | DERMALA INC. (US) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190290605-A1 | COMPOSITIONS AND METHODS FOR TREATING ECZEMA | CUTA, PEF1, ELOVL6 | MEN1 2525/4885KMT2A 4364/4885CYP2C19 405/4885 |
| US-11364214-B2 | Compositions and methods for treating eczema | CUTA, PEF1, ELOVL6 | MEN1 2525/4885KMT2A 4364/4885CYP2C19 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.